Topics in 10: Wilms Tumor

Published: 2019-08-07

181 Views

0 Likes

0 Shares

0 Comments

StayCurrentMD

View profile →

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

Ray Hinke — host
Dr. Andrew Davidoff — guest
Speaker 3 — host

Chapters

0:00Introduction and Epidemiology — Introduction to the Topics in 10 series and overview of Wilms tumor epidemiology, including incidence, age distribution, survival rates, and the critical distinction between favorable and anaplastic histology.
1:17Clinical Presentation and Diagnostic Workup — Discussion of typical presentation (asymptomatic abdominal mass), associated symptoms, and comprehensive diagnostic workup including ultrasound, CT imaging protocols, evaluation for bilateral disease, intravascular extension, and metastatic spread.
2:55Staging System — Detailed explanation of the Children's Oncology Group surgical-pathologic staging system for Wilms tumor, from stage 1 (confined within renal capsule) through stage 5 (bilateral disease).
4:03Treatment of Unilateral Disease — Comprehensive discussion of treatment approach for unilateral Wilms tumor, including rationale for upfront resection, stage-specific chemotherapy regimens, importance of lymph node sampling, and management of anaplastic histology.
6:49Management of Bilateral Disease — Treatment strategy for stage 5 (bilateral) Wilms tumor, including neoadjuvant chemotherapy approach, timing of surgery, and nephron-sparing surgical techniques.
8:37Intravascular Tumor Extension — Management strategies for Wilms tumor with intravascular extension, including surgical approaches based on anatomic extent and indications for neoadjuvant chemotherapy or cardiopulmonary bypass.
9:53Metastatic Disease Management — Discussion of stage 4 disease with focus on pulmonary metastases and the new response-based treatment approach that stratifies patients into rapid responders (avoiding radiation) versus slow/incomplete responders (requiring intensified therapy and whole lung irradiation).
11:03Summary and Conclusion — Rapid recap of clinical pearls covering all major management principles and closing remarks about the podcast series.

Key claims

0:00Wilms tumor is the second most common intra-abdominal tumor in children and fifth most common tumor in children overall — Ray Hinke
0:28Approximately 75% of Wilms tumor cases occur in children younger than 5 years of age, with peak incidence at 2 to 3 years of age — Dr. Andrew Davidoff
0:28Survival for patients with Wilms tumor when considered as a whole is currently greater than 90% — Dr. Andrew Davidoff
0:28Anaplastic histology comprises only about 10% of Wilms tumor cases but contributes to over 50% of Wilms tumor mortality — Dr. Andrew Davidoff
1:20Children with Wilms tumor typically present with an asymptomatic abdominal mass — Dr. Andrew Davidoff
1:20Associated signs and symptoms such as malaise, pain, microscopic or gross hematuria are found in only about 25% of children with Wilms tumor, as is hypertension — Dr. Andrew Davidoff
1:46The workup of a child with suspected Wilms tumor usually begins with ultrasound — Dr. Andrew Davidoff
1:46CT of the abdomen and pelvis is generally the definitive imaging study of choice for patients suspected of having a renal tumor based on ultrasound — Dr. Andrew Davidoff
1:46Intravascular tumor extension occurs in about 6% of Wilms tumor cases — Dr. Andrew Davidoff
2:44The most common site of metastatic spread of Wilms tumor is the lungs — Dr. Andrew Davidoff
2:44A chest CT should be included in the initial evaluation of a child suspected of having a Wilms tumor — Dr. Andrew Davidoff
2:59Localized Wilms tumors that are confined within the renal capsule are stage 1 — Dr. Andrew Davidoff
2:59Wilms tumors that penetrate the renal capsule but are resected with negative margins are stage 2 — Dr. Andrew Davidoff
2:59Stage 3 Wilms tumor includes circumstances such as biopsy or rupture (preoperative or intraoperative), positive resection margin or gross residual disease, lymph node involvement, or administration of preoperative chemotherapy — Dr. Andrew Davidoff
2:59Metastatic disease occurs in about 12% of Wilms tumor patients and is considered stage 4 — Dr. Andrew Davidoff
2:59Patients with synchronous bilateral Wilms tumor are stage 5 — Dr. Andrew Davidoff
4:06For unilateral tumors, upfront resection with regional lymph node sampling is currently the recommendation from the Children's Oncology Group — Dr. Andrew Davidoff
4:06Most Wilms tumors are resectable at presentation because even large tumors rarely invade surrounding structures — Dr. Andrew Davidoff
4:06Failure to perform upfront resection and instead administering neoadjuvant chemotherapy in COG results in classification as stage 3, mandating flank irradiation and doxorubicin, each associated with significant long-term toxicities — Dr. Andrew Davidoff
4:06Treatment of favorable histology Wilms tumor stage 1 or 2 is limited to vincristine and actinomycin D — Dr. Andrew Davidoff
4:06In rare circumstances when tumor is stage 1, weighs less than 550 grams (tumor plus kidney), and patient is less than 2 years of age, no adjuvant chemotherapy is given — Dr. Andrew Davidoff
4:06The presence of nodal involvement is associated with an increased incidence of tumor relapse and a poorer prognosis — Dr. Andrew Davidoff
4:06Lymph node sampling should be performed even in the absence of abnormal nodes on preoperative imaging or gross inspection during operative exploration, since these circumstances don't reliably predict lymph node negativity — Dr. Andrew Davidoff
4:06Partial nephrectomy for patients with unilateral non-syndromic disease and laparoscopic nephrectomy are not currently standard of care and should generally only be performed in the context of a clinical trial — Dr. Andrew Davidoff
4:06Anaplastic histology is associated with significantly worse outcome and is treated with more intensive chemotherapy — Dr. Andrew Davidoff
4:06A distinction is made between focal and diffuse anaplasia when determining specific adjuvant therapy — Dr. Andrew Davidoff
6:53About 5% of children with Wilms tumor will present with synchronous bilateral disease or stage 5 disease — Dr. Andrew Davidoff
6:53Patients with bilateral Wilms tumor receive neoadjuvant chemotherapy with three drugs to shrink tumors prior to surgery and facilitate preservation of normal renal parenchyma due to increased risk of renal failure — Dr. Andrew Davidoff
6:53A biopsy is not required in children with bilateral solid renal masses as bilateral Wilms tumor is the very likely diagnosis — Dr. Andrew Davidoff
6:53Biopsies of bilateral renal masses rarely detect anaplasia even when it does exist in the tumor mass — Dr. Andrew Davidoff
6:53A biopsy in bilateral disease doesn't mandate subsequent radiation as it does in patients with unilateral Wilms tumor — Dr. Andrew Davidoff
6:53Bilateral nephron-sparing surgery should be considered in all patients with bilateral Wilms tumor and should be performed after either 6 or 12 weeks of neoadjuvant chemotherapy — Dr. Andrew Davidoff
6:53Longer courses of preoperative chemotherapy than 6 or 12 weeks are definitely discouraged in bilateral Wilms tumor — Dr. Andrew Davidoff
8:42Tumor extension into the renal vein and proximal inferior vena cava can in most cases be removed en bloc with the kidney and tumor — Dr. Andrew Davidoff
8:42Primary resection of tumors with extension above the level of the hepatic veins or into the atrium is associated with higher operative morbidity, so neoadjuvant chemotherapy is generally used in these circumstances — Dr. Andrew Davidoff
8:42Thrombus extending above the hepatic veins that persists after neoadjuvant chemotherapy probably requires cardiopulmonary bypass to safely remove the full extent of disease — Dr. Andrew Davidoff
9:58About 12% of Wilms tumor patients will have evidence of hematogenous metastases at diagnosis with 80% of these being pulmonary metastases — Dr. Andrew Davidoff
9:58A new response-based approach is being used for patients with stage 4 disease in the Children's Oncology Group — Dr. Andrew Davidoff
9:58Stage 4 patients treated with three-drug chemotherapy who have radiographic disappearance of lung metastases or tissue confirmation that residual nodules don't contain viable tumor at week 6 are considered rapid responders and won't receive pulmonary irradiation — Dr. Andrew Davidoff
10:47Patients who don't have complete resolution of pulmonary nodules at 6 weeks are considered slow or incomplete responders, will be switched to more intensive chemotherapy regimen, and will receive whole lung irradiation — Dr. Andrew Davidoff

Open questions

What are the specific age and weight limits currently being considered by COG for expanding the no-adjuvant-chemotherapy criteria beyond stage 1 tumors less than 550 grams in patients under 2 years?
What is the optimal duration of neoadjuvant chemotherapy for bilateral Wilms tumor (6 weeks versus 12 weeks)?
What are the long-term renal function outcomes for patients treated with bilateral nephron-sparing surgery?

This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.

Wilms Tumor: Staging, Surgical Timing, and Response-Based Treatment

The episode's teaching points arranged as a structured lesson, building from the basics up to the finer points. Written by Kai from the episode transcript and reviewed before publishing.

For trainees · Teaching arc · AI-written, human-reviewed

Histology determines everything that follows

Anaplastic histology is the single most important prognostic factor. It comprises only 10% of cases but accounts for over 50% of Wilms tumor mortality 0:28. This 10-to-50 ratio means that when you see anaplasia on pathology, you are looking at a fundamentally different disease with a fundamentally different trajectory. The distinction between focal and diffuse anaplasia further refines treatment intensity 4:06. Favorable histology, by contrast, carries survival greater than 90% when considered as a whole 0:28.

The COG rationale for upfront resection rests on two facts

Most Wilms tumors are resectable at presentation because even large tumors rarely invade surrounding structures 4:06. This is the clinical reality that permits primary surgery. The second fact is procedural: administering neoadjuvant chemotherapy in the Children's Oncology Group protocol automatically classifies the tumor as stage 3, mandating flank irradiation and doxorubicin, each associated with significant long-term toxicities 4:06. The European protocols favor neoadjuvant chemotherapy; COG does not, and the reason is this staging consequence. For stage 1 or 2 favorable histology disease, treatment is limited to vincristine and actinomycin D 4:06. In rare circumstances—stage 1, tumor plus kidney weighing less than 550 grams, patient younger than 2 years—no adjuvant chemotherapy is given at all 4:06.

Lymph node sampling is mandatory regardless of what you see

Nodal involvement is associated with increased tumor relapse and poorer prognosis 4:06. The teaching point is that lymph node sampling must be performed even when nodes appear normal on preoperative imaging or gross inspection during operative exploration, because these assessments do not reliably predict lymph node negativity 4:06. This is a judgment call that has been settled by data: visual inspection is insufficient.

Bilateral disease inverts the treatment sequence

Patients with synchronous bilateral Wilms tumor receive neoadjuvant chemotherapy with three drugs to shrink tumors prior to surgery 6:53. The goal is preservation of normal renal parenchyma because these patients face increased risk of renal failure. Bilateral nephron-sparing surgery should be considered in all patients with bilateral disease and should be performed after either 6 or 12 weeks of neoadjuvant chemotherapy 6:53. Longer courses are discouraged 6:53. A biopsy is not required in children with bilateral solid renal masses because bilateral Wilms tumor is the very likely diagnosis 6:53, and biopsies rarely detect anaplasia even when it exists in the tumor mass 6:53. Importantly, a biopsy in bilateral disease does not mandate subsequent radiation as it does in unilateral Wilms tumor 6:53.

Intravascular extension above the hepatic veins changes the operative plan

Tumor extension into the renal vein and proximal inferior vena cava can in most cases be removed en bloc with the kidney and tumor 8:42. Primary resection of tumors with extension above the level of the hepatic veins or into the atrium is associated with higher operative morbidity, so neoadjuvant chemotherapy is generally used in these circumstances 8:42. Thrombus extending above the hepatic veins that persists after neoadjuvant chemotherapy probably requires cardiopulmonary bypass to safely remove the full extent of disease 8:42. The hepatic veins are the decision point.

Response-based treatment for metastatic disease spares some patients from radiation

Stage 4 patients treated with three-drug chemotherapy who have radiographic disappearance of lung metastases or tissue confirmation that residual nodules don't contain viable tumor at week 6 are considered rapid responders 9:58. These patients continue three-drug chemotherapy but do not receive pulmonary irradiation. Patients who do not have complete resolution of pulmonary nodules at 6 weeks are considered slow or incomplete responders, are switched to a more intensive chemotherapy regimen, and receive whole lung irradiation 10:47. The 6-week reassessment is the pivot: it separates patients who can avoid radiation from those who cannot.

Takeaways from this story

Anaplastic histology comprises 10% of cases but accounts for over 50% of Wilms tumor mortality—histology determines treatment intensity.
COG favors upfront resection because neoadjuvant chemotherapy mandates stage 3 classification, requiring flank radiation and doxorubicin.
Lymph node sampling is mandatory even when nodes appear normal—imaging and gross inspection don't reliably predict nodal negativity.
Bilateral disease receives neoadjuvant chemotherapy for 6-12 weeks to enable nephron-sparing surgery; longer courses are discouraged.
Stage 4 patients with complete radiographic response at 6 weeks avoid pulmonary irradiation; incomplete responders receive intensified therapy and radiation.

Topic overview

This educational podcast provides a focused overview of Wilms tumor, the second most common intra-abdominal malignancy in children. The discussion covers epidemiology (peak incidence 2-3 years, >90% overall survival), the critical prognostic distinction between favorable and anaplastic histology (10% of cases but >50% of mortality), diagnostic workup including imaging protocols, and the Children's Oncology Group staging system. Treatment approaches are detailed for unilateral disease (upfront radical nephrectomy with lymph node sampling followed by stage-appropriate chemotherapy), bilateral disease (neoadjuvant chemotherapy followed by nephron-sparing surgery), intravascular extension (approach based on anatomic extent), and metastatic disease (new response-based protocols to minimize pulmonary radiation).

Key takeaways

Anaplastic histology drives mortality: 10% of cases but >50% of deaths. Distinguish focal vs diffuse for treatment intensity. (0:28)
Upfront nephrectomy is COG standard for unilateral tumors; neoadjuvant chemo mandates stage 3 classification with flank XRT. (4:06)
Sample lymph nodes even if imaging/inspection normal—nodal involvement predicts relapse and changes stage/treatment. (4:06)
Bilateral disease (stage 5): neoadjuvant chemo 6-12 wks, then nephron-sparing surgery. Longer courses discouraged. (6:53)
Stage 4 rapid responders (lung mets clear by week 6) avoid pulmonary XRT; slow responders escalate to intensive chemo + XRT. (9:58)

Keywords

Wilms tumor anaplastic histology favorable histology hematuria hypertension intravascular tumor extension pulmonary metastases bilateral Wilms tumor renal failure ultrasound CT abdomen and pelvis chest CT echocardiography radical nephrectomy lymph node sampling

Hashtags

Hashtags will be added soon through AI processing

Transcript

Click "Show Transcript" to view the full text (11255 characters)

It's hard to stay on top of the rapidly changing literature in the limited hours we have in a day. So here at Stay Current, we are starting an ultra-focused podcast series, topics in 10, for those times you need just the cliff notes. Let's get to it. Have you ever asked, What exactly is Wilms' tumor? Wilms' tumor is the second most common intra-abdominal tumor in children, and fifth most common tumor in children overall, and its management is often changing. Dr. Andrew Davidoff, Chairman of Surgery at St. Jude's Children's Research Hospital, joins us to give us the essentials. Approximately 75% of the cases occur in children younger than 5 years of age, with a peak incidence at 2 to 3 years of age. Thankfully, survival for patients with Wilms' tumor, when considered as a whole, is currently greater than 90%. However, a critical prognostic factor that profoundly impacts outcome is histology. This is divided simply into two broad types, favorable and unfavorable, or anaplastic histology. The latter group comprises, thankfully, only about 10% of cases, but does contribute to over 50% of Wilms' tumor mortality. Talk to me about how these children present, typically. Well, interestingly, children with Wilms' tumor typically present with an asymptomatic abdominal mass. Associated signs and symptoms such as malaise, pain, microscopic, or gross hematuria are found in only about 25% of the children, as is hypertension. So, when a child presents with an abdominal mass, what's the typical workup? The workup of a child with an intra-abdominal mass that you suspect of being a Wilms' tumor usually begins with ultrasound. CT of the abdomen and pelvis is generally the definitive imaging study of choice for those patients who are suspected of having a renal tumor based on ultrasound. CT will confirm the presence of a solid renal mass and will also afford the opportunity to visualize the contralateral kidney to confirm its presence and function and to exclude synchronous bilateral disease. Intravascular tumor extension occurs in about 6% of Wilms' tumor cases. Therefore, this should be specifically investigated in preoperative evaluation as it may alter the timing and conduct of surgery. If intracardiac extension of tumor thrombus is suspected, this can be assessed by echocardiography. And where does Wilms metastasize to? The most common site of metastatic spread of Wilms' tumor is the lungs, and so a chest CT should be included in the initial evaluation of a child suspected of having a Wilms' tumor. Can you go over the staging of Wilms' tumor for me? Sure. So the children's oncology group currently uses a surgical pathologic staging system in which localized Wilms' tumors that are confined within the renal capsule are stage 1, while those that penetrate the renal capsule but are resected with negative margins are stage 2. Circumstances that make Wilms' tumor stage 3 are various and include biopsy or rupture, either preoperative or intraoperative, positive resection margin or gross residual disease, lymph node involvement, or the administration of preoperative chemotherapy. Metastatic disease, which occurs in about 12% of patients, is considered stage 4, although the local stage should also be evaluated, as this will determine whether abdominal radiation is indicated and to what field. Patients with synchronous bilateral Wilms' tumor are stage 5, but here again, local stage for each side should still be evaluated. Talk to me about the treatment of a child who's diagnosed with Wilms' tumor. Sure. So, for unilateral tumors, upfront resection with regional lymph node sampling is currently the recommendation from the children's oncology group, and by upfront resection, that's generally radical nephrectomy. And the reason why this approach is favored by the COG is twofold. First, although Wilms' tumors can grow to a large size, even large tumors rarely invade surrounding structures, and so because of this, most Wilms' tumors are resectable at presentation. Secondly, the failure to perform an upfront resection, but instead administering neoadjuvant chemotherapy in the COG, results in the classification of a tumor as stage 3, thus mandating the use of other therapies, including flank irradiation and doxorubicin, each of which is associated with significant long-term toxicities. Treatment of favorable histology Wilms' tumor, that's stage 1 or 2, is just limited to vincristin and actinomycin D. And more recently, in rare circumstances, when the tumor is stage 1, weighs less than 550 grams, that's the tumor weight plus the kidney, and the patient is less than 2 years of age, no adjuvant chemotherapy is given. And actually, raising the age and the weight limits of the tumor plus kidney are currently being considered for study by COG. But it is important that careful lymph node sampling be done, as it's a critical part of any operation for Wilms' tumor, because the presence of nodal involvement is associated with an increased incidence of tumor relapse and a poorer prognosis, although effective, albeit more intensive therapy, exists to treat children with stage 3 disease. So, lymph node sampling should be performed even in the absence of abnormal nodes on preoperative imaging or on gross inspection during operative exploration, since these circumstances really don't reliably predict lymph node negativity. Partial nephrectomy for patients with unilateral, non-syndromic disease, and or laparoscopic nephrectomy are really not currently standard of care and should generally only be performed in the context of a clinical trial. And finally, as I mentioned previously, anaplastic histology is unfortunately associated with a significantly worse outcome and so is treated with more intensive chemotherapy. There is a distinction, though, made between focal and diffuse anaplasia when determining specific adjuvant therapy. Talk to me about a child that presents with bilateral Wilms tumor. Of course. So, about 5% of children with Wilms tumor will present with synchronous bilateral disease or stage 5 disease. And in these circumstances, due to an increased risk of renal failure for these patients, they receive neoadjuvant chemotherapy chemotherapy with three drugs as used for patients with stage 3 or stage 4 favorable histology Wilms tumor in an effort to shrink the tumors prior to surgery and to facilitate the preservation of normal renal parenchyma. Also treated in this manner are patients with Wilms tumor arising in a solitary kidney or, as I mentioned before, those with unilateral Wilms tumor who are at an increased risk for developing metachronous tumor, although these patients usually don't receive doxorubicin as part of their neoadjuvant chemotherapy. A biopsy is not required in children with bilateral solid renal masses as bilateral Wilms tumor is the very likely diagnosis. Although the histologic subtype, favorable or unfavorable, won't be known, studies have shown that biopsies of bilateral renal masses rarely detect anaplasia even when it does exist in the tumor mass. However, a biopsy, if performed, doesn't mandate subsequent radiation as it does in patients with unilateral Wilms tumor. Bilateral nephron-sparing surgery should really be considered in all patients with bilateral Wilms tumor. This should be performed after either 6 or 12 weeks of neoadjuvant chemotherapy. Longer courses of preoperative chemotherapy are definitely discouraged. So, how do you manage a patient that presents with intravascular tumor extension? Yeah, so these cases can be quite challenging. It should be determined by preoperative imaging that there is or isn't intravascular tumor extension. then its presence or absence confirmed intraoperatively. Tumor extension into the renal vein and proximal inferior vena cava can in most cases be removed and blocked with the kidney and tumor. Thrombus that extends further into the vena cava can also be withdrawn from the IVC after gaining proximal and distal control. Proximal control can generally be achieved if the superior extent of the thrombus is below the level of the hepatic veins. However, primary resection of tumors with extension above the level of the hepatic veins or especially into the atrium is associated with higher operative morbidity and so neoadjuvant chemotherapy is generally used in these circumstances. Thrombus that extends above the hepatic veins and which persists to this extent after neoadjuvant chemotherapy probably requires cardiopulmonary bypass to safely remove the full extent of disease. So what if the patient presents with metastases? Yeah, so about 12% of Wilms tumor patients will have evidence of hematogenous metastases at diagnosis with 80% of these being pulmonary metastases. Interestingly, a new response-based approach is being used for the patients with stage 4 disease in the children's oncology group. These patients treated with three-drug chemotherapy who have radiographic disappearance of their lung metastases or who have tissue confirmation that residual nodules don't contain viable tumor at week 6 imaging re-evaluation will be considered rapid responders will continue on this three-drug chemotherapy regimen but won't receive pulmonary irradiation. And patients who don't respond? Patients who don't have complete resolution of pulmonary nodules at 6 weeks will be considered slow or incomplete responders. They will be switched to more intensive chemotherapy regimen and will receive whole lung irradiation. You did it! You just made it through a blitzkrieg on Wilms tumor. So, here's a quick recap of our clinical pearls. Wilms is the most common renal tumor in children. It has an outstanding overall survival at greater than 90% but that's worse with anaplastic histology. The treatment for unilateral disease is a radical nephrectomy with lymph node sampling followed by venchristine and actinomycin B for stages 1 and 2. For stage 3, add doxorubicin and radiation therapy. For bilateral disease, neoadjuvant 3 drug therapy and then nephron sparing surgery, if possible, is the way to go. If there's intravascular involvement, the approach is based on the extent of the tumor. If it's above the hepatic veins, give neoadjuvant chemotherapy. And for lung metastasis, management is now response-based to avoid pulmonary radiation. So, that was our first topic in 10. What do you think? Should we continue doing these podcasts? What topics do you want us to cover? Let us know by messaging us on the Stay Current and Pediatric Surgery app or give us a shout-out on Facebook or Twitter. This chapter is created and edited by Todd Ponsky, Alex Kassar, Alex Skibbins, and myself, Ray Hinke. Remember, knowledge should be free. I was a very good to be a very good you, the one. I was a very good to be a very good to be a very good and the one. I was a very good to be a very good to be a very good to be a very good to be a very good to be a very good to be a very good to be a very good to be a very good and a very good to be a very good to be a very good to be a very good to be a very good to be a very good to be a very good to be a very good to be a very good to be a very good to be a very good the one. to be a very good bar the one, the one, bar, you

Comments

Loading comments...